

| Report: CIB.20D103.MY | Issued: 13 May 2020 Page: 1 of 5 |
|---|---|
| Test Report: | EN 13624:2013 |
| | Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of fungicidal or yeasticidal activity in the medical area – Test method and requirements (phase 2, step 1) |
| Identification of the test laboratory: | Abbott Analytical Ltd Unit 2, Hickmans Road, Birkenhead, CH41 1JH, United Kingdom |
| Identification of the client: | NanoTech Solutions Norway AS Hofslundveien 6, N-3090 Hof Norway |
| Identification of the sample: | 20D/103 |
| Name of the product: | NanoSanis |
| Batch number/reference and expiry date (if available): | N/A |
| Date of delivery: | 22 April 2020 |
| Storage conditions: | Room temperature in darkness |
| Product diluent recommended by the manufacturer for use: | Not disclosed |
| Active substance(s) and their concentrations (s) (optional): | Not disclosed |
| Appearance of the product: | Clear colourless liquid |
| | |

Notes:

- 1) The test results in this report relate only to the sample(s) tested.
- 2) This test report may not be reproduced except in full, adapted, altered or used to create a derivative work, without written approval from Abbott Analytical Ltd.

Abbott Analytical Ltd Unit 2, Hickmans Road, Birkenhead, CH41 1JH, United Kingdom



| Report: CIB.20D103.MY | Issued: 13 May 2020 | Page: 2 of 5 | | |
|---|---|--------------|--|--|
| Test method and its validation: | | | | |
| Method: | Dilution-neutralisation | | | |
| Neutraliser: | 100.0 g/l Polysorbate 80 + 30.0 g/l Lecithin + 30.0 g/l Tryptone Soya Broth + 5.0 g/l Sodium thiosulphate 1.0 g/l L-histidine (Neutraliser B) | | | |
| Neutraliser validation: | Validated in accordance with EN 13624:2013 (5.5.2) | | | |
| Experimental conditions: | | | | |
| Period of analysis: | 11 May 2020 to 13 May 2020 | | | |
| Product test concentration(s): | Neat | | | |
| Diluent used for product test solution(s): | N/A | | | |
| Contact time(s): | 5 min ± 10 s | | | |
| Test temperature(s): | 20°C ± 1°C | | | |
| Interfering substance: | 0.3 g/l bovine albumin (clean c | onditions) | | |
| Temperature of incubation: | 30°C ± 1°C | | | |
| Identification of the bacterial strain(s) used: | Candida albicans (DSM 1386) | | | |

Deviations:

None

Remarks:

- 1) All test conditions are as requested by the client, irrespective of whether these are in accordance with EN 13624:2013 (5.4.2) or EN 13624:2013 (5.5.1.1).
- 2) Products can only be tested at a concentration of 80% or less as some dilution is always produced by adding the test organisms and interfering substance.



Report: CIB.20D103.MY

Issued: 13 May 2020

Page: 3 of 5

Requirements:

The product shall demonstrate at least a 4 decimal log (lg) reduction against every test organism.

Conclusion:

According to EN 13624:2013, this sample of NanoSanis possesses yeasticidal activity against the referenced strain of *Candida albicans*, when tested neat with a contact time of 5 minutes at 20°C under clean conditions.

Report prepared by:

Approved by:

Signed:

kan

Signed:

Name:

Date:

Position:

Tony Watson General Manager 13 May 2020

Name:Karl CumingsPosition:MicrobiologistDate:13 May 2020

Abbott Analytical Ltd Unit 2, Hickmans Road, Birkenhead, CH41 1JH, United Kingdom



Report: CIB.20D103.MY

Issued: 13 May 2020

Page: 4 of 5

RST 019 (Issue 2)

Results: EN 13624:2013

| Test organism: | Candida albicans | | (DSM 1386) |
|---------------------------------|------------------|-------------------------|------------------|
| Date of test: | 11 May 2020 | | |
| Test temperature: | 20°C ± 1°C | Incubation temperature: | 30°C ± 1°C |
| Dilution-neutralisation method: | Pour plate | Number of plates: | 1 / ml |
| Neutraliser: | В | Test conditions: | Clean conditions |

Validation and controls:

| Validation suspension (Nv_0) | | Experimental conditions | | | Neutraliser or filtration | | | Method validation (C) | | | |
|--|------|-------------------------|---|-------|---------------------------|---|-------------------|-----------------------|---|--------|--------------------|
| | | | control (A | 1) | | control (E | | Product conc.: Neat | | Neat | |
| Vc1 | 52 | <i>π</i> = | Vc1 | 48 | <u></u> <i></i> | Vc1 | 46 | <u></u> <i></i> | Vc1 | 48 | <u></u> <i>π</i> = |
| Vc2 | 50 | 51 | Vc2 | 46 | 47 | Vc2 | 48 | 47 | Vc2 | 48 | 48 |
| $30 \le \overline{\mu}$ of $Nv_0 \le 160$? | | | $\overline{\varkappa}$ of $A \ge 0.5 \times \overline{\varkappa}$ of Nv_0 ? | | | $\overline{\varkappa}$ of $B \ge 0.5 \times \overline{\varkappa}$ of Nv_0 | | | $\overline{\varkappa}$ of $C \ge 0.5 \times \overline{\varkappa}$ of Nv_0 ? | | |
| 🗵 yes | 🗆 no | | ⊠ yes | 🗆 no | | (or Nv _B / 2 | 1000) ? | | ⊠ yes | □ no | |
| | | | | | | 🗵 yes | 🗆 no | | | | |
| Validation suspension (Nv _B) | | | | | | | | | | | |
| | | _ | | | | | | | | | |
| Vc1 | 57 | <u></u> <i>μ</i> = | | | | | | | | | |
| Vc2 | 52 | 54.5 | | | | | | | | | |
| $30 \le \overline{\mu}$ of $Nv_{\rm B}$ / $1000 \le 160$? | | | | | | | | | | | |
| 🛛 yes | 🗆 no | | | | | | | | | | |
| | | | _ | | | | | | | | |
| Test suspension (N and N _o): | | | | N | Vc1 | Vc2 | ν wm = | 2.36 x 10 | ⁷ ; | lg N = | 7.37 |
| | | | | 10 -5 | 232 | 248 | $N_0 = N/$ | 10 ; | lg No = | 6.37 | |

| | | | | | | | 0 - | |
|-------|--------------|---------|-----------------|-----|-----|----------------------------------|--------------------------------------|-----------------------------|
| | | | 10 -6 | 20 | 19 | 6.17 ≤ lg N₀ ≤ 6.70 ? ⊠ye | | s □no |
| | | | | | | - | - | |
| Test: | Conc. of the | Contact | Dilution | Vc1 | Vc2 | <i>Na</i> (и х 10 or | a ($\overline{\mu}$ x 10 or lg Na | |
| | product | time | step | | | й wm x 10) | | (lg N _o - lg Na) |
| | Neat | 5 min | 10 ⁰ | 0 | 0 | <140 <2.15 | | >4.22 |
| | | | 10 -1 | 0 | 0 |] | | |



Report: CIB.20D103.MY

Issued: 13 May 2020

Page: 5 of 5

Explanations:

- *Vc* count per ml (one plate or more)
- $\overline{\varkappa}$ average of Vc1 and Vc2 (1 + 2 duplicate)
- $\overline{\varkappa}$ wm weighted mean of $\overline{\varkappa}$
- *N* number of cells per ml in the test suspension
- N_0 number of cells in the test mixture at the beginning of the contact time ($N_0 = N / 10$)
- *Na* number of survivors per ml in the test mixture at the end of the contact time (before neutralisation or filtration)
- $R \qquad \text{reduction (lg } R = \text{lg } N_0 \text{lg } Na)$
- *Nv* number of cells per ml in the validation suspension
- Nv_0 number of cells in the validation mixtures at the beginning of the contact time ($Nv_0 = Nv / 10$)
- Nv_B number of cells per ml in the neutraliser control validation suspension
- *A* number of survivors per ml in the experimental conditions control mixture
- *B* number of survivors per ml in the neutraliser or filtration control mixture
- *C* number of survivors per ml in the method validation mixture